Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

The coronavirus pandemic is reigniting a fierce debate over compounded drugs

June 9, 2020, STAT News

Julie Dohm is quoted in STAT News regarding the FDA’s temporary policy allowing smaller pharmacies to make certain drugs for treating COVID-19 without first receiving a patient’s prescription for the drug. The condition for this new policy is that the pharmacies sell the drugs to a hospital that can prove it could not source the drugs from elsewhere. Ms. Dohm calls those provisions “pivotal” to the current regulatory framework. “If traditional compounding pharmacies can ship compounded drugs without patient specific prescriptions then there would be very little incentive, maybe none, for any compounding pharmacy to decide to become an [large-scale] facility,” she adds.

Share this article: